SmarTest Calprotectin
SmarTest Calprotectin is made and published by Preventis GmbH. AppBrain is an independent app data site and isn't affiliated with Preventis GmbH. The app name, icon, screenshots and description belong to Preventis GmbH and are shown as published on the App Store.
AppBrain's verdict
- Last updated
- May 4, 2026
Rankings
App Store top chartsApp Store Rankings for SmarTest Calprotectin
Competitors
Similar apps and more from Preventis GmbHReleases
Updates seen on the App Store- Version
- 1.3.1
- Launched
- July 2021
No changelog data
User feedback
Ratings and reviews on the App StoreComments on SmarTest Calprotectin for iOS
We don't have enough comments to show example comments. Please check back later.
Technology
Found in the app by AppBrain- Price
- Free
- App size
- 153.4 MB
- Content rating
- High
Technologies used by SmarTest Calprotectin
About the app and developer
About SmarTest Calprotectin
SmarTest Calprotectin is a health & fitness app developed by Preventis GmbH.
What is the rating of SmarTest Calprotectin?
SmarTest Calprotectin has no ratings yet.
Is SmarTest Calprotectin free?
SmarTest Calprotectin is free. The app size is 153.39 MB. The latest version available is 1.3.1. The last update was on May 4, 2026.
What are the requirements for SmarTest Calprotectin?
The app has a content rating of High Maturity. The app has been available on the App Store since July 2021.
Developer information for Preventis GmbH
Address:
Frequently asked questions about SmarTest Calprotectin
Is SmarTest Calprotectin free?
Yes. SmarTest Calprotectin is free on the App Store.
Is SmarTest Calprotectin still available?
Yes. SmarTest Calprotectin is on the App Store, and the last update we saw was on May 4, 2026.
How large is SmarTest Calprotectin?
SmarTest Calprotectin is 153.39 MB.
Is SmarTest Calprotectin suitable for children?
App Store gives SmarTest Calprotectin a high maturity rating. It is meant for adults.
Who made SmarTest Calprotectin?
SmarTest Calprotectin was developed by Preventis GmbH. It is listed in the health & fitness category on the App Store.
What are the best alternatives to SmarTest Calprotectin?
People looking at SmarTest Calprotectin also look at these health & fitness apps: CalproSmart, Crohn's Disease by AZoMedical, Nutri-IBD, IBD Classes, IBDoc®.
Store listing
By Preventis GmbH, from the App StoreDescription by Preventis GmbH Written by the developer, not by AppBrain. Click to read.
SmarTest Calprotectin is a manually performed rapid test including a smartphone app developed for its evaluation to quantitatively detect the inflammatory marker Calprotectin in human stool. It provides assistance in the follow-up and therapy monitoring of chronic inflammatory bowel diseases (e.g. Crohn's disease or ulcerative colitis).
Calprotectin is a calcium-binding protein that is produced in large quantities by specific immune cells, the neutrophil granulocytes (neutrophils), and released during inflammatory events. In inflammatory bowel diseases, neutrophils migrate into the intestinal lumen and release calprotectin, which can then be detected in the stool. However, on the basis of clinical symptoms, it is often difficult to distinguish patients with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis from patients suffering from the usual irritable bowel syndrome. With the additional determination of calprotectin in the stool, however, inflammation in the intestinal tract can be diagnosed with clinical certainty. An increased calprotectin concentration in the stool provides information about the presence of inflammation in the intestine. This non-invasive determination of calprotectin can often spare patients with common irritable bowel syndrome an unnecessary invasive colonoscopy in case of low concentrations. Since scientific studies have shown that the concentration of calprotectin in stool correlates well with histological and endoscopic findings of disease activity in patients with IBD, the calprotectin concentration in stool can also be used diagnostically to objectively document therapeutic success. Furthermore, it can be used to monitor currently asymptomatic IBD patients in order to detect and control relapse of IBD at an early stage.